MX389103B - Anticuerpos contra ticagrelor y métodos de uso. - Google Patents

Anticuerpos contra ticagrelor y métodos de uso.

Info

Publication number
MX389103B
MX389103B MX2017004196A MX2017004196A MX389103B MX 389103 B MX389103 B MX 389103B MX 2017004196 A MX2017004196 A MX 2017004196A MX 2017004196 A MX2017004196 A MX 2017004196A MX 389103 B MX389103 B MX 389103B
Authority
MX
Mexico
Prior art keywords
antibodies
ticagrelor
methods
disclosure
metabolites
Prior art date
Application number
MX2017004196A
Other languages
English (en)
Other versions
MX2017004196A (es
Inventor
Andrew Buchanan
Feenagh Keyes
Mark Penney
Philip Newton
Sven Nylander
Tord Inghardt
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2017004196A publication Critical patent/MX2017004196A/es
Publication of MX389103B publication Critical patent/MX389103B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La descripción proporciona en general anticuerpos y fragmentos de anticuerpos de unión a antígenos que se unen a ticagrelor y metabolitos de ticagrelor. La descripción proporciona también composiciones que comprenden los anticuerpos, moléculas de ácidos nucleicos que codifican los anticuerpos, métodos de tratar a un paciente, que comprende administrar los anticuerpos y métodos de producir y utilizar los anticuerpos.
MX2017004196A 2014-10-01 2015-09-30 Anticuerpos contra ticagrelor y métodos de uso. MX389103B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462058458P 2014-10-01 2014-10-01
US201562114931P 2015-02-11 2015-02-11
PCT/EP2015/072606 WO2016050867A1 (en) 2014-10-01 2015-09-30 Antibodies to ticagrelor and methods of use

Publications (2)

Publication Number Publication Date
MX2017004196A MX2017004196A (es) 2017-07-19
MX389103B true MX389103B (es) 2025-03-20

Family

ID=54238444

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004196A MX389103B (es) 2014-10-01 2015-09-30 Anticuerpos contra ticagrelor y métodos de uso.
MX2022000242A MX2022000242A (es) 2014-10-01 2017-03-30 Anticuerpos contra ticagrelor y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000242A MX2022000242A (es) 2014-10-01 2017-03-30 Anticuerpos contra ticagrelor y metodos de uso.

Country Status (12)

Country Link
US (5) US9982061B2 (es)
EP (1) EP3201235A1 (es)
JP (2) JP6799530B2 (es)
KR (2) KR102594117B1 (es)
CN (2) CN113956361B (es)
AU (2) AU2015326869B2 (es)
CA (1) CA2963166C (es)
MX (2) MX389103B (es)
NZ (1) NZ730247A (es)
RU (1) RU2021125449A (es)
TW (2) TWI707870B (es)
WO (1) WO2016050867A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102594117B1 (ko) 2014-10-01 2023-10-26 메디뮨 리미티드 티카그렐로에 대한 항체 및 이의 사용 방법
WO2018212556A1 (en) * 2017-05-16 2018-11-22 Cj Healthcare Corporation A method for purifying an antibody or an antibody fragment thereof using affinity chromatography
CN107976497B (zh) * 2017-11-23 2020-11-10 重庆华邦制药有限公司 替格瑞洛中间体1的合成反应程度测定方法及应用
DK3852617T3 (da) * 2018-09-20 2025-10-20 Sfj Pharma X Inc Anvendelse af antistof fragmenter til revertering af ticagrelor-aktivitet
CN114432315B (zh) * 2020-11-05 2025-02-11 华东师范大学 一种预防、治疗疼痛的化合物及其应用
US20230192895A1 (en) * 2021-05-10 2023-06-22 Phasebio Pharmaceuticals, Inc. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
US20260022197A1 (en) * 2024-07-16 2026-01-22 SFJ Pharma X, Inc. Methods of reversing ticagrelor activity

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH03154867A (ja) * 1989-11-13 1991-07-02 Teijin Ltd １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AR017014A1 (es) 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
AU2001276842B2 (en) 2000-06-28 2007-04-26 Glycofi, Inc. Methods for producing modified glycoproteins
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP1572915A4 (en) 2002-04-11 2011-01-05 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS BY SPRAY DRYING
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
AU2003297320B8 (en) 2002-12-17 2008-02-21 Medimmune, Llc High pressure spray-dry of bioactive materials
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
CA2660463C (en) * 2006-08-11 2013-07-16 Schering Corporation Antibodies to il-17a
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
JP2014516982A (ja) 2011-06-01 2014-07-17 アストラゼネカ アクチボラグ 新規なチカグレロル共結晶
EP2729488A4 (en) 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9993251B2 (en) 2014-05-02 2018-06-12 W. L. Gore & Associates, Inc. Anastomosis devices
KR102594117B1 (ko) 2014-10-01 2023-10-26 메디뮨 리미티드 티카그렐로에 대한 항체 및 이의 사용 방법
KR102702288B1 (ko) 2016-12-23 2024-09-05 노파르티스 아게 항-인자 XI/XIa 항체를 사용한 치료 방법
CN110366429B (zh) 2017-03-01 2024-10-11 免疫医疗有限公司 单克隆抗体的配制品
DK3852617T3 (da) 2018-09-20 2025-10-20 Sfj Pharma X Inc Anvendelse af antistof fragmenter til revertering af ticagrelor-aktivitet
US20230192895A1 (en) 2021-05-10 2023-06-22 Phasebio Pharmaceuticals, Inc. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody

Also Published As

Publication number Publication date
AU2021209207B2 (en) 2024-03-14
US20210371546A1 (en) 2021-12-02
US20240101712A1 (en) 2024-03-28
CN106715473A (zh) 2017-05-24
US10487154B2 (en) 2019-11-26
AU2015326869B2 (en) 2021-04-29
US11773186B2 (en) 2023-10-03
KR20170061695A (ko) 2017-06-05
KR102594117B1 (ko) 2023-10-26
JP2021011485A (ja) 2021-02-04
AU2021209207A1 (en) 2021-08-19
CA2963166C (en) 2023-10-03
RU2017114645A3 (es) 2019-05-07
US20160130366A1 (en) 2016-05-12
CN113956361A (zh) 2022-01-21
TW202104271A (zh) 2021-02-01
CN106715473B (zh) 2021-11-23
EP3201235A1 (en) 2017-08-09
US10954308B2 (en) 2021-03-23
WO2016050867A1 (en) 2016-04-07
AU2015326869A1 (en) 2017-04-06
CN113956361B (zh) 2025-06-17
US12391768B2 (en) 2025-08-19
NZ730247A (en) 2022-11-25
TWI774071B (zh) 2022-08-11
RU2021125449A (ru) 2021-09-16
RU2017114645A (ru) 2018-11-07
US9982061B2 (en) 2018-05-29
TW201617370A (zh) 2016-05-16
KR20230153495A (ko) 2023-11-06
MX2022000242A (es) 2022-02-03
KR102767586B1 (ko) 2025-02-17
JP6799530B2 (ja) 2020-12-16
TWI707870B (zh) 2020-10-21
JP7027502B2 (ja) 2022-03-01
MX2017004196A (es) 2017-07-19
CA2963166A1 (en) 2016-04-07
JP2017535252A (ja) 2017-11-30
US20180319897A1 (en) 2018-11-08
RU2754468C2 (ru) 2021-09-02
US20190077882A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
CY1121934T1 (el) Αντισωματα anti-fcrn
PH12016501644A1 (en) Binding proteins and methods of use thereof
EP4417263A3 (en) Cd3 binding antibodies
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
PH12017500890A1 (en) Antibody drug conjugates
EA201791485A1 (ru) Анти-cd47-антитела и их применения
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX389103B (es) Anticuerpos contra ticagrelor y métodos de uso.
EP3256495A4 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
PH12016501366A1 (en) Novel anti-baff antibodies
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
BR112017013420A2 (pt) anticorpo adam17 humanizado